Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. 2013

Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany.

PET using O-(2-[(18)F]fluoroethyl)-L-tyrosine ((18)F-FET) allows improved imaging of tumor extent of cerebral gliomas in comparison to MRI. In experimental brain infarction and hematoma, an unspecific accumulation of (18)F-FET has been detected in the area of reactive astrogliosis which is a common cellular reaction in the vicinity of cerebral gliomas. The aim of this study was to investigate possible (18)F-FET uptake in the area of reactive gliosis in the vicinity of untreated and irradiated rat gliomas. METHODS F98-glioma cells were implanted into the caudate nucleus of 33 Fisher CDF rats. Sixteen animals remained untreated and in 17 animals the tumor was irradiated by Gamma Knife 5-8 days after implantation (2/50 Gy, 3/75 Gy, 6/100 Gy, 6/150 Gy). After 8-17 days of tumor growth the animals were sacrificed following injection of (18)F-FET. Brains were removed, cut in coronal sections and autoradiograms of (18)F-FET distribution were produced and compared with histology (toluidine blue) and reactive astrogliosis (GFAP staining). (18)F-FET uptake in the tumors and in areas of reactive astrocytosis was evaluated by lesion to brain ratios (L/B). RESULTS Large F98-gliomas were present in all animals showing increased (18)F-FET-uptake which was similar in irradiated and non-irradiated tumors (L/B: 3.9 ± 0.8 vs. 4.0 ± 1.3). A pronounced reactive astrogliosis was noted in the vicinity of all tumors that showed significantly lower (18)F-FET-uptake than the tumors (L/B: 1.5 ± 0.4 vs. 3.9 ± 1.1). The area of (18)F-FET-uptake in the tumor was congruent with histological tumor extent in 31/33 animals. In 2 rats irradiated with 150 Gy, however, high (18)F-FET uptake was noted in the area of astrogliosis which led to an overestimation of the tumor size. CONCLUSIONS Reactive astrogliosis in the vicinity of gliomas generally leads to only a slight (18)F-FET-enrichment that appears not to affect the correct definition of tumor extent for treatment planning.

UI MeSH Term Description Entries
D008297 Male Males
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D005911 Gliosis The production of a dense fibrous network of neuroglia; includes astrocytosis, which is a proliferation of astrocytes in the area of a degenerative lesion. Astrocytosis,Astrogliosis,Glial Scar,Astrocytoses,Glial Scars,Scar, Glial
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D014443 Tyrosine A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin. L-Tyrosine,Tyrosine, L-isomer,para-Tyrosine,L Tyrosine,Tyrosine, L isomer,para Tyrosine
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
October 2020, Molecular imaging and biology,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
May 2010, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
April 2006, Nuclear medicine and biology,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
March 2017, European journal of nuclear medicine and molecular imaging,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
March 2005, Brain : a journal of neurology,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
September 2020, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
May 2017, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
December 2020, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
August 2017, EJNMMI research,
Marc D Piroth, and Jeyakamalini Prasath, and Antje Willuweit, and Gabriele Stoffels, and Bernd Sellhaus, and Ansel van Osterhout, and Stefanie Geisler, and Nadim J Shah, and Michael J Eble, and Heinz H Coenen, and Karl-Josef Langen
March 2014, Nuclear medicine communications,
Copied contents to your clipboard!